| Value | ₹0.02 Cr |
|---|
NSE filing, NSE: INFINIUM. Summary written from the filing by ALFA Finder's alert engine.
Infinium Pharmachem Ltd: key numbers
- Share price
- ₹281.00
- Market cap
- ₹391.0 Cr
- Revenue (annual)
- ₹189.6 Cr
- Net profit (annual)
- ₹12.15 Cr
- P/E (TTM)
- 32.2×Sector 45.9×
- Promoter holding
- 64.91%
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Infinium Pharmachem Ltd
All →Infinium Pharmachem Other Announcement
Infinium Pharmachem Limited filed its quarterly SEBI Regulation 74(5) compliance certificate for the period ending September 30, 2026, confirming all shares are held in demat form.
Infinium Pharmachem SME to Main Board Migration
Infinium Pharmachem Limited submitted its Annual Secretarial Compliance Report for 2026. This filing supports the company's application to migrate from the NSE SME Emerge platform to the Main Board.
Infinium Pharmachem Annual General Meeting
Infinium Pharmachem Limited announced that the resolution for migrating its equity shares from the NSE Emerge platform to the mainboard was passed via postal ballot.
Infinium Pharmachem Credit Rating
ICRA assigned a new [ICRA]BBB (Stable) rating to Infinium Pharmachem's ₹52.20 Crore credit facilities. The assignment covers cash credit, term loans, and unallocated limits from ICICI Bank and SBI.
Infinium Pharmachem Annual General Meeting
Infinium Pharmachem Limited held its 22nd Annual General Meeting on September 17, 2026. Shareholders transacted ordinary and special business, including director appointments and remuneration revisions.
Infinium Pharmachem SME to Main Board Migration
Infinium Pharmachem Limited issued a postal ballot notice to seek shareholder approval for migrating its equity shares from the NSE Emerge platform to the main board.
Other adverse business impact announcements
All →Oriental Rail Infrastructure Adverse Business Impact
Oriental Rail's subsidiary Oriental Foundry had a fire at its Kutch plant on 28 October 2026. Damage is minimal, operations are unaffected and the loss is insured.
Capillary Technologies India Adverse Business Impact
Capillary Technologies received KPMG's final forensic report on a cyber-enabled payment fraud at a step-down subsidiary. Four disputed payments totalled EUR 3.04 million, about Rs.32.24 Crore.
- Value
- ₹32.24 Cr
Windlas Biotech Adverse Business Impact
Windlas Biotech disclosed a cyber security incident on 30 October 2026. It states no material impact on core operations, finances or business continuity.
Neogen Chemicals Adverse Business Impact
Neogen Chemicals reports continued fire disruption at MPP3; replacement plant partly built with trial runs underway. Recognized damage totals ₹348.16 crore; production shifted to other sites.
- Value
- ₹348.2 Cr
Hindustan Organic Chemicals Adverse Business Impact
Hindustan Organic Chemicals temporarily shuts down its Kochi Hydrogen plant from 29 October 2026 for pipeline repair and urgent maintenance. Reopening date to be communicated separately.
IIFL Capital Services Adverse Business Impact
IIFL Capital Services' subsidiary surrendered its SEBI Investment Adviser registration, effective October 28, 2026. The company states there is no material monetary impact and no penalty.